TDMS Study 05158-04 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MOLYBDENUM TRIOXIDE DATE: 04/04/96
EXPERIMENT: 05158 TEST: 04 TIME: 02:49:15
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01-ES-95240 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 61369C
PATHOLOGIST: R. MILLER CAS: 1313-27-5
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MOLYBDENUM TRIOXIDE DATE: 04/04/96
EXPERIMENT: 05158 TEST: 04 TIME: 02:49:15
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-95240 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 61369C
PATHOLOGIST: R. MILLER CAS: 1313-27-5
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Cortex
Adrenal Medulla
Bone Marrow
Brain
Clitoral Gland
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Larynx
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MOLYBDENUM TRIOXIDE DATE: 04/04/96
EXPERIMENT: 05158 TEST: 04 TIME: 02:49:15
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-95240 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 61369C
PATHOLOGIST: R. MILLER CAS: 1313-27-5
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF MOLYBDENUM TRIOXIDE
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hepatocellular Carcinoma
Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
All Organs Malignant Tumors
Malignant and Benign Tumors
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hemangiosarcoma
Hepatocellular Carcinoma
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Pituitary Gland: Pars Intermedia
Adenoma
Skin Sarcoma
Uterus Polyp Stromal
All Organs Hemangiosarcoma
Hemangiosarcoma or Hemangioma
====================================================================================================
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/49 (2%) 2/48 (4%) 0/50 (0%) | 1/50 (2%) 1/50 (2%) 1/49 (2%) 0/49 (0%) |
|ADJUSTED (b) | 2.8% 2.4% 8.0% 0.0% | 3.4% 3.2% 2.5% 0.0% |
|TERMINAL (d) | 1/36 (3%) 0/33 (0%) 2/25 (8%) 0/37 (0%) | 0/25 (0%) 1/31 (3%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | 733 (T) 692 733 (T) --- | 720 733 (T) 705 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.313N P=0.759 P=0.373 P=0.495N | P=0.294N P=0.722N P=0.710N P=0.462N |
|INCIDENTAL TUMOR | P=0.326N P=0.680N P=0.373 P=0.495N | P=0.354N P=0.751 P=0.746N P=0.590N |
|LOGISTIC REGRESSION | P=0.314N P=0.758N P=0.373 P=0.495N | P=0.315N P=0.738N P=0.746N P=0.480N |
|COCHRAN-ARMITAGE | P=0.323N | P=0.332N |
|FISHER EXACT | P=0.747 P=0.485 P=0.500N | P=0.753N P=0.747 P=0.505N |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 4/50 (8%) 4/50 (8%) 2/50 (4%) | 2/50 (4%) 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 2.8% 9.8% 15.1% 5.4% | 6.8% 6.5% 0.0% 0.0% |
|TERMINAL (d) | 1/36 (3%) 1/33 (3%) 3/25 (12%) 2/37 (5%) | 1/25 (4%) 2/31 (6%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | 733 (T) 580 715 733 (T) | 692 733 (T) --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.488N P=0.184 P=0.094 P=0.510 | P=0.109N P=0.627N P=0.190N P=0.192N |
|INCIDENTAL TUMOR | P=0.525N P=0.263 P=0.135 P=0.510 | P=0.118N P=0.665N P=0.201N P=0.248N |
|LOGISTIC REGRESSION | P=0.517N P=0.168 P=0.121 P=0.510 | P=0.123N P=0.660N P=0.212N P=0.223N |
|COCHRAN-ARMITAGE | P=0.532N | P=0.136N |
|FISHER EXACT | P=0.181 P=0.181 P=0.500 | P=0.691N P=0.247N P=0.247N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 0/50 (0%) 1/50 (2%) | 1/50 (2%) 0/50 (0%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 5.6% 0.0% 0.0% 2.4% | 2.9% 0.0% 2.4% 2.7% |
|TERMINAL (d) | 2/36 (6%) 0/33 (0%) 0/25 (0%) 0/37 (0%) | 0/25 (0%) 0/31 (0%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | 733 (T) --- --- 677 | 692 --- 689 699 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.643N P=0.258N P=0.322N P=0.482N | P=0.581 P=0.483N P=0.715N P=0.728N |
|INCIDENTAL TUMOR | P=0.682N P=0.258N P=0.322N P=0.473N | P=0.467 P=0.564N P=0.746N P=0.661 |
|LOGISTIC REGRESSION | P=0.662N P=0.258N P=0.322N P=0.488N | P=0.559 P=0.499N P=0.762 P=0.761N |
|COCHRAN-ARMITAGE | P=0.673N | P=0.559 |
|FISHER EXACT | P=0.247N P=0.247N P=0.500N | P=0.500N P=0.753N P=0.753N |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 4/50 (8%) 4/50 (8%) 3/50 (6%) | 3/50 (6%) 2/50 (4%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 8.3% 9.8% 15.1% 7.7% | 9.6% 6.5% 2.4% 2.7% |
|TERMINAL (d) | 3/36 (8%) 1/33 (3%) 3/25 (12%) 2/37 (5%) | 1/25 (4%) 2/31 (6%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | 733 (T) 580 715 677 | 692 733 (T) 689 699 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.465N P=0.486 P=0.315 P=0.644N | P=0.232N P=0.427N P=0.235N P=0.245N |
|INCIDENTAL TUMOR | P=0.514N P=0.590 P=0.388 P=0.637N | P=0.298N P=0.499N P=0.255N P=0.394N |
|LOGISTIC REGRESSION | P=0.497N P=0.506 P=0.380 P=0.640N | P=0.271N P=0.466N P=0.289N P=0.503N |
|COCHRAN-ARMITAGE | P=0.514N | P=0.277N |
|FISHER EXACT | P=0.500 P=0.500 P=0.661N | P=0.500N P=0.309N P=0.309N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/48 (4%) 0/48 (0%) 1/50 (2%) | 1/50 (2%) 0/49 (0%) 0/48 (0%) 1/46 (2%) |
|ADJUSTED (b) | 0.0% 6.1% 0.0% 2.7% | 4.0% 0.0% 0.0% 2.9% |
|TERMINAL (d) | 0/36 (0%) 2/33 (6%) 0/25 (0%) 1/37 (3%) | 1/25 (4%) 0/31 (0%) 0/33 (0%) 1/35 (3%) |
|FIRST INCIDENCE (DAYS) | --- 733 (T) --- 733 (T) | 733 (T) --- --- 733 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.635 P=0.219 (e) P=0.505 | P=0.588 P=0.457N P=0.445N P=0.685N |
|INCIDENTAL TUMOR | P=0.635 P=0.219 (e) P=0.505 | P=0.588 P=0.457N P=0.445N P=0.685N |
|LOGISTIC REGRESSION | P=0.635 P=0.219 (e) P=0.505 | P=0.588 P=0.457N P=0.445N P=0.685N |
|COCHRAN-ARMITAGE | P=0.621 | P=0.520 |
|FISHER EXACT | P=0.237 (e) P=0.500 | P=0.505N P=0.510N P=0.731 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 3/48 (6%) 0/48 (0%) 1/50 (2%) | 1/50 (2%) 0/49 (0%) 1/48 (2%) 2/46 (4%) |
|ADJUSTED (b) | 0.0% 9.1% 0.0% 2.7% | 4.0% 0.0% 3.0% 5.0% |
|TERMINAL (d) | 0/36 (0%) 3/33 (9%) 0/25 (0%) 1/37 (3%) | 1/25 (4%) 0/31 (0%) 1/33 (3%) 1/35 (3%) |
|FIRST INCIDENCE (DAYS) | --- 733 (T) --- 733 (T) | 733 (T) --- 733 (T) 534 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.593N P=0.106 (e) P=0.505 | P=0.284 P=0.457N P=0.699N P=0.570 |
|INCIDENTAL TUMOR | P=0.593N P=0.106 (e) P=0.505 | P=0.242 P=0.457N P=0.699N P=0.500 |
|LOGISTIC REGRESSION | P=0.593N P=0.106 (e) P=0.505 | P=0.214 P=0.457N P=0.699N P=0.461 |
|COCHRAN-ARMITAGE | P=0.620N | P=0.217 |
|FISHER EXACT | P=0.114 (e) P=0.500 | P=0.505N P=0.742 P=0.468 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 2/49 (4%) |
|ADJUSTED (b) | 0.0% 0.0% 3.6% 0.0% | 0.0% 0.0% 0.0% 5.2% |
|TERMINAL (d) | 0/36 (0%) 0/33 (0%) 0/25 (0%) 0/37 (0%) | 0/25 (0%) 0/31 (0%) 0/33 (0%) 1/35 (3%) |
|FIRST INCIDENCE (DAYS) | --- --- 715 --- | --- --- --- 664 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.754N (e) P=0.450 (e) | P=0.053 (e) (e) P=0.292 |
|INCIDENTAL TUMOR | P=0.851N (e) P=0.657 (e) | P=0.035 * (e) (e) P=0.223 |
|LOGISTIC REGRESSION | P=0.772N (e) P=0.475 (e) | P=0.040 * (e) (e) P=0.237 |
|COCHRAN-ARMITAGE | P=0.779N | P=0.040 * |
|FISHER EXACT | (e) P=0.500 (e) | (e) (e) P=0.242 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 20/50 (40%) 15/50 (30%) 19/50 (38%) 19/50 (38%) | 9/50 (18%) 11/50 (22%) 13/50 (26%) 16/49 (33%) |
|ADJUSTED (b) | 50.5% 37.9% 64.1% 48.4% | 32.2% 31.5% 35.2% 45.7% |
|TERMINAL (d) | 17/36 (47%) 9/33 (27%) 15/25 (60%) 17/37 (46%) | 7/25 (28%) 8/31 (26%) 10/33 (30%) 16/35 (46%) |
|FIRST INCIDENCE (DAYS) | 433 689 513 580 | 562 629 638 733 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.510N P=0.273N P=0.201 P=0.458N | P=0.213 P=0.586 P=0.482 P=0.304 |
|INCIDENTAL TUMOR | P=0.479 P=0.206N P=0.371 P=0.574 | P=0.107 P=0.473 P=0.352 P=0.215 |
|LOGISTIC REGRESSION | P=0.497 P=0.183N P=0.557 P=0.469N | P=0.093 P=0.471 P=0.352 P=0.151 |
|COCHRAN-ARMITAGE | P=0.455 | P=0.061 |
|FISHER EXACT | P=0.201N P=0.500N P=0.500N | P=0.402 P=0.235 P=0.074 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 18/50 (36%) 21/50 (42%) 13/50 (26%) | 19/50 (38%) 12/50 (24%) 16/50 (32%) 11/49 (22%) |
|ADJUSTED (b) | 27.0% 42.0% 46.6% 28.3% | 49.9% 31.9% 38.3% 26.3% |
|TERMINAL (d) | 5/36 (14%) 10/33 (30%) 5/25 (20%) 5/37 (14%) | 8/25 (32%) 7/31 (23%) 9/33 (27%) 6/35 (17%) |
|FIRST INCIDENCE (DAYS) | 350 448 365 408 | 469 600 562 350 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.310N P=0.162 P=0.028 * P=0.541 | P=0.065N P=0.053N P=0.147N P=0.028N* |
|INCIDENTAL TUMOR | P=0.442N P=0.100 P=0.153 P=0.515 | P=0.207N P=0.145N P=0.476N P=0.086N |
|LOGISTIC REGRESSION | P=0.492N P=0.072 P=0.133 P=0.372 | P=0.138N P=0.099N P=0.395N P=0.080N |
|COCHRAN-ARMITAGE | P=0.356N | P=0.134N |
|FISHER EXACT | P=0.138 P=0.044 * P=0.500 | P=0.097N P=0.338N P=0.071N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 30/50 (60%) 27/50 (54%) 34/50 (68%) 28/50 (56%) | 23/50 (46%) 22/50 (44%) 25/50 (50%) 27/49 (55%) |
|ADJUSTED (b) | 66.1% 60.4% 79.3% 60.6% | 61.7% 57.1% 59.7% 67.0% |
|TERMINAL (d) | 21/36 (58%) 16/33 (48%) 17/25 (68%) 19/37 (51%) | 12/25 (48%) 15/31 (48%) 17/33 (52%) 22/35 (63%) |
|FIRST INCIDENCE (DAYS) | 350 448 365 408 | 469 600 562 350 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.314N P=0.435N P=0.044 * P=0.375N | P=0.535 P=0.251N P=0.333N P=0.415N |
|INCIDENTAL TUMOR | P=0.474N P=0.441N P=0.256 P=0.462N | P=0.192 P=0.510N P=0.374 P=0.427 |
|LOGISTIC REGRESSION | P=0.479N P=0.410N P=0.361 P=0.451N | P=0.168 P=0.477N P=0.426 P=0.248 |
|COCHRAN-ARMITAGE | P=0.441N | P=0.161 |
|FISHER EXACT | P=0.343N P=0.266 P=0.420N | P=0.500N P=0.421 P=0.241 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 30/50 (60%) 27/50 (54%) 34/50 (68%) 28/50 (56%) | 23/50 (46%) 22/50 (44%) 25/50 (50%) 27/49 (55%) |
|ADJUSTED (b) | 66.1% 60.4% 79.3% 60.6% | 61.7% 57.1% 59.7% 67.0% |
|TERMINAL (d) | 21/36 (58%) 16/33 (48%) 17/25 (68%) 19/37 (51%) | 12/25 (48%) 15/31 (48%) 17/33 (52%) 22/35 (63%) |
|FIRST INCIDENCE (DAYS) | 350 448 365 408 | 469 600 562 350 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.314N P=0.435N P=0.044 * P=0.375N | P=0.535 P=0.251N P=0.333N P=0.415N |
|INCIDENTAL TUMOR | P=0.474N P=0.441N P=0.256 P=0.462N | P=0.192 P=0.510N P=0.374 P=0.427 |
|LOGISTIC REGRESSION | P=0.479N P=0.410N P=0.361 P=0.451N | P=0.168 P=0.477N P=0.426 P=0.248 |
|COCHRAN-ARMITAGE | P=0.441N | P=0.161 |
|FISHER EXACT | P=0.343N P=0.266 P=0.420N | P=0.500N P=0.421 P=0.241 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 9/50 (18%) 14/50 (28%) 10/49 (20%) 9/50 (18%) | 1/50 (2%) 4/50 (8%) 8/49 (16%) 9/49 (18%) |
|ADJUSTED (b) | 23.5% 37.8% 29.8% 22.5% | 3.7% 11.0% 23.5% 24.8% |
|TERMINAL (d) | 7/36 (19%) 11/33 (33%) 5/25 (20%) 7/37 (19%) | 0/25 (0%) 2/31 (6%) 7/33 (21%) 8/35 (23%) |
|FIRST INCIDENCE (DAYS) | 651 653 440 576 | 729 610 720 667 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.272N P=0.146 P=0.270 P=0.570N | P=0.042 * P=0.236 P=0.045 * P=0.032 * |
|INCIDENTAL TUMOR | P=0.338N P=0.265 P=0.511 P=0.544N | P=0.019 * P=0.145 P=0.041 * P=0.019 * |
|LOGISTIC REGRESSION | P=0.322N P=0.205 P=0.464 P=0.571N | P=0.018 * P=0.184 P=0.036 * P=0.016 * |
|COCHRAN-ARMITAGE | P=0.335N | P=0.013 * |
|FISHER EXACT | P=0.171 P=0.480 P=0.602N | P=0.181 P=0.014 * P=0.007 ** |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 16/50 (32%) 14/49 (29%) 10/50 (20%) | 2/50 (4%) 2/50 (4%) 0/49 (0%) 6/49 (12%) |
|ADJUSTED (b) | 4.9% 40.7% 43.3% 25.3% | 5.8% 5.2% 0.0% 16.3% |
|TERMINAL (d) | 1/36 (3%) 11/33 (33%) 8/25 (32%) 8/37 (22%) | 0/25 (0%) 0/31 (0%) 0/33 (0%) 5/35 (14%) |
|FIRST INCIDENCE (DAYS) | 544 580 513 629 | 642 629 --- 632 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.462 P<0.001 ** P<0.001 ** P=0.020 * | P=0.044 * P=0.655N P=0.192N P=0.235 |
|INCIDENTAL TUMOR | P=0.382 P<0.001 ** P=0.002 ** P=0.013 * | P=0.005 ** P=0.559 P=0.364N P=0.065 |
|LOGISTIC REGRESSION | P=0.385 P<0.001 ** P<0.001 ** P=0.017 * | P=0.024 * P=0.694 P=0.256N P=0.140 |
|COCHRAN-ARMITAGE | P=0.371 | P=0.024 * |
|FISHER EXACT | P<0.001 ** P<0.001 ** P=0.014 * | P=0.691N P=0.253N P=0.128 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 27/50 (54%) 21/49 (43%) 18/50 (36%) | 3/50 (6%) 6/50 (12%) 8/49 (16%) 15/49 (31%) |
|ADJUSTED (b) | 27.7% 64.8% 56.1% 43.4% | 9.3% 15.6% 23.5% 40.1% |
|TERMINAL (d) | 8/36 (22%) 19/33 (58%) 10/25 (40%) 14/37 (38%) | 0/25 (0%) 2/31 (6%) 7/33 (21%) 13/35 (37%) |
|FIRST INCIDENCE (DAYS) | 544 580 440 576 | 642 610 720 632 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.432N P=0.001 ** P=0.005 ** P=0.123 | P=0.004 ** P=0.320 P=0.205 P=0.015 * |
|INCIDENTAL TUMOR | P=0.538 P=0.002 ** P=0.044 * P=0.105 | P<0.001 ** P=0.139 P=0.128 P=0.001 ** |
|LOGISTIC REGRESSION | P=0.541N P=0.001 ** P=0.020 * P=0.106 | P<0.001 ** P=0.223 P=0.152 P=0.003 ** |
|COCHRAN-ARMITAGE | P=0.547 | P<0.001 ** |
|FISHER EXACT | P<0.001 ** P=0.022 * P=0.093 | P=0.243 P=0.094 P=0.001 ** |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 2/50 (4%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 0.0% 6.5% 2.0% 0.0% |
|TERMINAL (d) | 0/36 (0%) 0/33 (0%) 0/25 (0%) 0/37 (0%) | 0/25 (0%) 2/31 (6%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | --- 733 (T) 288 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.345N P=0.286 P=0.500 (e) |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.190N P=0.286 (e) (e) |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.312N P=0.286 (e) (e) |
|COCHRAN-ARMITAGE | (e) | P=0.383N |
|FISHER EXACT | (e) (e) (e) | P=0.247 P=0.500 (e) |
|=================================================================================================================================|
| |
|Ovary |
| Cystadenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 1/50 (2%) 2/49 (4%) 3/48 (6%) 0/46 (0%) |
|ADJUSTED (b) | | 3.4% 6.5% 8.4% 0.0% |
|TERMINAL (d) | | 0/25 (0%) 2/31 (6%) 2/33 (6%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | | 720 733 (T) 692 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.195N P=0.565 P=0.393 P=0.462N |
|INCIDENTAL TUMOR | | P=0.234N P=0.498 P=0.356 P=0.621N |
|LOGISTIC REGRESSION | | P=0.225N P=0.543 P=0.349 P=0.486N |
|COCHRAN-ARMITAGE | | P=0.266N |
|FISHER EXACT | | P=0.492 P=0.293 P=0.521N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/47 (0%) 0/47 (0%) 0/46 (0%) 0/47 (0%) | 9/49 (18%) 8/48 (17%) 9/48 (19%) 9/49 (18%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 28.1% 25.4% 22.4% 24.9% |
|TERMINAL (d) | 0/34 (0%) 0/31 (0%) 0/24 (0%) 0/36 (0%) | 5/25 (20%) 6/29 (21%) 3/32 (9%) 8/35 (23%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | 511 709 670 698 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.410N P=0.384N P=0.414N P=0.361N |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.543N P=0.482N P=0.598N P=0.487N |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.564N P=0.491N P=0.596 P=0.563N |
|COCHRAN-ARMITAGE | (e) | P=0.529 |
|FISHER EXACT | (e) (e) (e) | P=0.519N P=0.584 P=0.603N |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/47 (0%) 0/47 (0%) 0/46 (0%) 0/47 (0%) | 9/49 (18%) 8/48 (17%) 10/48 (21%) 9/49 (18%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 28.1% 25.4% 25.1% 24.9% |
|TERMINAL (d) | 0/34 (0%) 0/31 (0%) 0/24 (0%) 0/36 (0%) | 5/25 (20%) 6/29 (21%) 4/32 (13%) 8/35 (23%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | 511 709 670 698 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.395N P=0.384N P=0.499N P=0.361N |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.524N P=0.482N P=0.525 P=0.487N |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.551N P=0.491N P=0.500 P=0.563N |
|COCHRAN-ARMITAGE | (e) | P=0.539 |
|FISHER EXACT | (e) (e) (e) | P=0.519N P=0.480 P=0.603N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Intermedia |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/47 (0%) 1/47 (2%) 0/46 (0%) 2/47 (4%) | 0/49 (0%) 0/48 (0%) 0/48 (0%) 2/49 (4%) |
|ADJUSTED (b) | 0.0% 2.4% 0.0% 5.1% | 0.0% 0.0% 0.0% 5.7% |
|TERMINAL (d) | 0/34 (0%) 0/31 (0%) 0/24 (0%) 1/36 (3%) | 0/25 (0%) 0/29 (0%) 0/32 (0%) 2/35 (6%) |
|FIRST INCIDENCE (DAYS) | --- 689 --- 686 | --- --- --- 733 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.170 P=0.520 (e) P=0.254 | P=0.063 (e) (e) P=0.315 |
|INCIDENTAL TUMOR | P=0.112 P=0.674 (e) P=0.266 | P=0.063 (e) (e) P=0.315 |
|LOGISTIC REGRESSION | P=0.154 P=0.495 (e) P=0.244 | P=0.063 (e) (e) P=0.315 |
|COCHRAN-ARMITAGE | P=0.149 | P=0.043 * |
|FISHER EXACT | P=0.500 (e) P=0.247 | (e) (e) P=0.247 |
|=================================================================================================================================|
| |
|Skin |
| Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 1/50 (2%) 3/50 (6%) 4/50 (8%) |
|ADJUSTED (b) | 0.0% 0.0% 4.0% 0.0% | 0.0% 3.2% 7.5% 10.2% |
|TERMINAL (d) | 0/36 (0%) 0/33 (0%) 1/25 (4%) 0/37 (0%) | 0/25 (0%) 1/31 (3%) 0/33 (0%) 1/35 (3%) |
|FIRST INCIDENCE (DAYS) | --- --- 733 (T) --- | --- 733 (T) 653 664 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.756N (e) P=0.427 (e) | P=0.065 P=0.543 P=0.165 P=0.095 |
|INCIDENTAL TUMOR | P=0.756N (e) P=0.427 (e) | P=0.017 * P=0.543 P=0.129 P=0.030 * |
|LOGISTIC REGRESSION | P=0.756N (e) P=0.427 (e) | P=0.027 * P=0.543 P=0.118 P=0.064 |
|COCHRAN-ARMITAGE | P=0.779N | P=0.044 * |
|FISHER EXACT | (e) P=0.500 (e) | P=0.500 P=0.121 P=0.059 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 1/50 (2%) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 2.7% | 0.0% 0.0% 5.9% 0.0% |
|TERMINAL (d) | 0/36 (0%) 0/33 (0%) 0/25 (0%) 1/37 (3%) | 0/25 (0%) 0/31 (0%) 1/33 (3%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- 733 (T) | --- --- 723 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.244 (e) (e) P=0.505 | P=0.630N (e) P=0.297 (e) |
|INCIDENTAL TUMOR | P=0.244 (e) (e) P=0.505 | P=0.689N (e) P=0.280 (e) |
|LOGISTIC REGRESSION | P=0.244 (e) (e) P=0.505 | P=0.654N (e) P=0.284 (e) |
|COCHRAN-ARMITAGE | P=0.221 | P=0.675N |
|FISHER EXACT | (e) (e) P=0.500 | (e) P=0.247 (e) |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 3/50 (6%) 2/49 (4%) 1/50 (2%) | 2/50 (4%) 2/50 (4%) 1/49 (2%) 2/49 (4%) |
|ADJUSTED (b) | 2.8% 8.2% 8.0% 2.7% | 8.0% 5.8% 3.0% 5.7% |
|TERMINAL (d) | 1/36 (3%) 2/33 (6%) 2/25 (8%) 1/37 (3%) | 2/25 (8%) 1/31 (3%) 1/33 (3%) 2/35 (6%) |
|FIRST INCIDENCE (DAYS) | 733 (T) 664 733 (T) 733 (T) | 733 (T) 681 733 (T) 733 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.388N P=0.294 P=0.373 P=0.756N | P=0.565N P=0.624N P=0.403N P=0.569N |
|INCIDENTAL TUMOR | P=0.408N P=0.361 P=0.373 P=0.756N | P=0.588N P=0.665N P=0.403N P=0.569N |
|LOGISTIC REGRESSION | P=0.403N P=0.321 P=0.373 P=0.756N | P=0.620N P=0.664N P=0.403N P=0.569N |
|COCHRAN-ARMITAGE | P=0.421N | P=0.608 |
|FISHER EXACT | P=0.309 P=0.492 P=0.753N | P=0.691N P=0.508N P=0.684 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/50 (6%) 2/49 (4%) 1/50 (2%) | 2/50 (4%) 2/50 (4%) 1/49 (2%) 2/49 (4%) |
|ADJUSTED (b) | 5.6% 8.2% 8.0% 2.7% | 8.0% 5.8% 3.0% 5.7% |
|TERMINAL (d) | 2/36 (6%) 2/33 (6%) 2/25 (8%) 1/37 (3%) | 2/25 (8%) 1/31 (3%) 1/33 (3%) 2/35 (6%) |
|FIRST INCIDENCE (DAYS) | 733 (T) 664 733 (T) 733 (T) | 733 (T) 681 733 (T) 733 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.278N P=0.480 P=0.558 P=0.490N | P=0.565N P=0.624N P=0.403N P=0.569N |
|INCIDENTAL TUMOR | P=0.293N P=0.550 P=0.558 P=0.490N | P=0.588N P=0.665N P=0.403N P=0.569N |
|LOGISTIC REGRESSION | P=0.289N P=0.522 P=0.558 P=0.490N | P=0.620N P=0.664N P=0.403N P=0.569N |
|COCHRAN-ARMITAGE | P=0.305N | P=0.608 |
|FISHER EXACT | P=0.500 P=0.684 P=0.500N | P=0.691N P=0.508N P=0.684 |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # # |
|----------- | | |
|OVERALL (a) | | 4/50 (8%) 3/50 (6%) 0/50 (0%) 3/50 (6%) |
|ADJUSTED (b) | | 16.0% 9.1% 0.0% 8.6% |
|TERMINAL (d) | | 4/25 (16%) 2/31 (6%) 0/33 (0%) 3/35 (9%) |
|FIRST INCIDENCE (DAYS) | | 733 (T) 709 --- 733 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.435N P=0.388N P=0.033N* P=0.319N |
|INCIDENTAL TUMOR | | P=0.456N P=0.424N P=0.033N* P=0.319N |
|LOGISTIC REGRESSION | | P=0.481N P=0.427N P=0.033N* P=0.319N |
|COCHRAN-ARMITAGE | | P=0.550N |
|FISHER EXACT | | P=0.500N P=0.059N P=0.500N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 2/50 (4%) 0/50 (0%) | 0/50 (0%) 1/50 (2%) 0/50 (0%) 3/50 (6%) |
|ADJUSTED (b) | 2.8% 0.0% 7.4% 0.0% | 0.0% 2.2% 0.0% 8.0% |
|TERMINAL (d) | 1/36 (3%) 0/33 (0%) 1/25 (4%) 0/37 (0%) | 0/25 (0%) 0/31 (0%) 0/33 (0%) 2/35 (6%) |
|FIRST INCIDENCE (DAYS) | 733 (T) --- 715 --- | --- 594 --- 664 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.417N P=0.517N P=0.388 P=0.495N | P=0.054 P=0.523 (e) P=0.174 |
|INCIDENTAL TUMOR | P=0.451N P=0.517N P=0.503 P=0.495N | P=0.017 * P=0.419 (e) P=0.132 |
|LOGISTIC REGRESSION | P=0.427N P=0.517N P=0.436 P=0.495N | P=0.041 * P=0.530 (e) P=0.127 |
|COCHRAN-ARMITAGE | P=0.441N | P=0.040 * |
|FISHER EXACT | P=0.500N P=0.500 P=0.500N | P=0.500 (e) P=0.121 |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 3/50 (6%) 1/50 (2%) | 0/50 (0%) 1/50 (2%) 1/50 (2%) 3/50 (6%) |
|ADJUSTED (b) | 2.8% 0.0% 11.3% 2.7% | 0.0% 2.2% 3.0% 8.0% |
|TERMINAL (d) | 1/36 (3%) 0/33 (0%) 2/25 (8%) 1/37 (3%) | 0/25 (0%) 0/31 (0%) 1/33 (3%) 2/35 (6%) |
|FIRST INCIDENCE (DAYS) | 733 (T) --- 715 733 (T) | --- 594 733 (T) 664 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.620 P=0.517N P=0.196 P=0.756N | P=0.091 P=0.523 P=0.555 P=0.174 |
|INCIDENTAL TUMOR | P=0.596 P=0.517N P=0.271 P=0.756N | P=0.039 * P=0.419 P=0.555 P=0.132 |
|LOGISTIC REGRESSION | P=0.612 P=0.517N P=0.236 P=0.756N | P=0.066 P=0.530 P=0.555 P=0.127 |
|COCHRAN-ARMITAGE | P=0.592 | P=0.066 |
|FISHER EXACT | P=0.500N P=0.309 P=0.753N | P=0.500 P=0.500 P=0.121 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 4/50 (8%) 0/50 (0%) 1/50 (2%) | 1/50 (2%) 1/50 (2%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 5.6% 12.1% 0.0% 2.7% | 3.3% 2.9% 0.0% 2.4% |
|TERMINAL (d) | 2/36 (6%) 4/33 (12%) 0/25 (0%) 1/37 (3%) | 0/25 (0%) 0/31 (0%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | 733 (T) 733 (T) --- 733 (T) | 709 709 --- 650 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.224N P=0.296 P=0.322N P=0.490N | P=0.698 P=0.727N P=0.453N P=0.723N |
|INCIDENTAL TUMOR | P=0.225N P=0.296 P=0.322N P=0.490N | P=0.600 P=0.693 P=0.483N P=0.661 |
|LOGISTIC REGRESSION | P=0.225N P=0.296 P=0.322N P=0.490N | P=0.673 P=0.753N P=0.484N P=0.762N |
|COCHRAN-ARMITAGE | P=0.245N | P=0.673 |
|FISHER EXACT | P=0.339 P=0.247N P=0.500N | P=0.753N P=0.500N P=0.753N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated |
| Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 2/50 (4%) 2/50 (4%) | 3/50 (6%) 5/50 (10%) 8/50 (16%) 6/50 (12%) |
|ADJUSTED (b) | 5.6% 5.3% 5.1% 4.6% | 10.4% 12.9% 19.9% 16.3% |
|TERMINAL (d) | 2/36 (6%) 1/33 (3%) 0/25 (0%) 1/37 (3%) | 2/25 (8%) 2/31 (6%) 3/33 (9%) 5/35 (14%) |
|FIRST INCIDENCE (DAYS) | 733 (T) 664 442 328 | 636 592 603 632 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.594N P=0.681 P=0.615 P=0.686N | P=0.436 P=0.444 P=0.203 P=0.398 |
|INCIDENTAL TUMOR | P=0.613 P=0.639N P=0.624N P=0.686N | P=0.131 P=0.302 P=0.089 P=0.197 |
|LOGISTIC REGRESSION | P=0.617 P=0.679N P=0.673N P=0.668 | P=0.309 P=0.354 P=0.108 P=0.264 |
|COCHRAN-ARMITAGE | P=0.627 | P=0.311 |
|FISHER EXACT | P=0.691N P=0.691N P=0.691N | P=0.357 P=0.100 P=0.243 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Osteosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 4.8% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/36 (0%) 0/33 (0%) 0/25 (0%) 0/37 (0%) | 0/25 (0%) 0/31 (0%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | 581 --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.260N P=0.227N P=0.215N P=0.232N |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.546N P=0.328N P=0.500N P=0.674N |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.228N P=0.209N P=0.241N P=0.197N |
|COCHRAN-ARMITAGE | (e) | P=0.262N |
|FISHER EXACT | (e) (e) (e) | P=0.247N P=0.247N P=0.247N |
|=================================================================================================================================|
| |
|All Organs |
| Osteosarcoma or Osteoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 4.8% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/36 (0%) 0/33 (0%) 0/25 (0%) 0/37 (0%) | 0/25 (0%) 0/31 (0%) 0/33 (0%) 0/35 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | 581 --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.260N P=0.227N P=0.215N P=0.232N |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.546N P=0.328N P=0.500N P=0.674N |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.228N P=0.209N P=0.241N P=0.197N |
|COCHRAN-ARMITAGE | (e) | P=0.262N |
|FISHER EXACT | (e) (e) (e) | P=0.247N P=0.247N P=0.247N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 28/50 (56%) 26/50 (52%) 28/50 (56%) 28/50 (56%) | 25/50 (50%) 24/50 (48%) 30/50 (60%) 26/50 (52%) |
|ADJUSTED (b) | 67.8% 58.8% 83.9% 66.3% | 72.2% 62.7% 69.6% 70.2% |
|TERMINAL (d) | 23/36 (64%) 15/33 (45%) 20/25 (80%) 23/37 (62%) | 16/25 (64%) 17/31 (55%) 20/33 (61%) 24/35 (69%) |
|FIRST INCIDENCE (DAYS) | 433 580 440 576 | 511 610 638 667 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.432N P=0.516N P=0.075 P=0.513N | P=0.230N P=0.212N P=0.453N P=0.145N |
|INCIDENTAL TUMOR | P=0.471 P=0.282N P=0.311 P=0.542 | P=0.541N P=0.421N P=0.380 P=0.396N |
|LOGISTIC REGRESSION | P=0.522 P=0.371N P=0.452 P=0.532N | P=0.532 P=0.409N P=0.382 P=0.542N |
|COCHRAN-ARMITAGE | P=0.478 | P=0.457 |
|FISHER EXACT | P=0.421N P=0.580N P=0.580N | P=0.500N P=0.211 P=0.500 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 20/50 (40%) 36/50 (72%) 35/50 (70%) 24/50 (48%) | 28/50 (56%) 25/50 (50%) 29/50 (58%) 25/50 (50%) |
|ADJUSTED (b) | 44.7% 77.6% 73.3% 49.7% | 62.8% 55.6% 59.1% 54.0% |
|TERMINAL (d) | 12/36 (33%) 23/33 (70%) 13/25 (52%) 13/37 (35%) | 9/25 (36%) 12/31 (39%) 13/33 (39%) 14/35 (40%) |
|FIRST INCIDENCE (DAYS) | 350 448 365 328 | 469 220 288 350 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.209N P=0.006 ** P=0.001 ** P=0.356 | P=0.194N P=0.196N P=0.281N P=0.140N |
|INCIDENTAL TUMOR | P=0.302N P<0.001 ** P=0.010 * P=0.259 | P=0.411 P=0.500N P=0.314 P=0.423 |
|LOGISTIC REGRESSION | P=0.337N P<0.001 ** P=0.006 ** P=0.209 | P=0.549N P=0.408N P=0.319 P=0.513 |
|COCHRAN-ARMITAGE | P=0.255N | P=0.372N |
|FISHER EXACT | P=0.001 ** P=0.002 ** P=0.273 | P=0.344N P=0.500 P=0.344N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 04 PAGE 17
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 40/50 (80%) 44/50 (88%) 45/50 (90%) 42/50 (84%) | 40/50 (80%) 39/50 (78%) 43/50 (86%) 40/50 (80%) |
|ADJUSTED (b) | 84.9% 89.7% 93.5% 84.0% | 84.8% 84.5% 86.0% 85.1% |
|TERMINAL (d) | 29/36 (81%) 28/33 (85%) 22/25 (88%) 29/37 (78%) | 18/25 (72%) 24/31 (77%) 26/33 (79%) 28/35 (80%) |
|FIRST INCIDENCE (DAYS) | 350 448 365 328 | 469 220 288 350 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.331N P=0.223 P=0.012 * P=0.522 | P=0.159N P=0.186N P=0.225N P=0.113N |
|INCIDENTAL TUMOR | P=0.528 P=0.156 P=0.143 P=0.349 | P=0.385 P=0.541N P=0.205 P=0.393 |
|LOGISTIC REGRESSION | P=0.516 P=0.178 P=0.189 P=0.357 | P=0.542 P=0.520N P=0.212 P=0.586 |
|COCHRAN-ARMITAGE | P=0.561 | P=0.546 |
|FISHER EXACT | P=0.207 P=0.131 P=0.398 | P=0.500N P=0.298 P=0.598N |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).